PMID- 34583637
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20240403
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Sep 28
TI  - Current progress of fluoroquinolones-increased risk of aortic aneurysm and 
      dissection.
PG  - 470
LID - 10.1186/s12872-021-02258-1 [doi]
LID - 470
AB  - Aortic aneurysm (AA) and aortic dissection (AD) are major life-threatening 
      diseases around the world. AA is a localized or diffuse dilation of the aorta, 
      while AD is the separation of the layers creating a false lumen within the aortic 
      wall. Fluoroquinolones (FQ) remain one of the most important kind of antibiotics 
      and have a wider clinical use and broad antibacterial spectrum. FQ were also 
      reported to treat infected AA. The most common adverse events (AEs) of FQ are 
      mild and reversible, like headaches, diarrhea and nausea. Due to FQ-related 
      serious AEs, such as tendonitis and tendon rupture, chondrotoxicity, or retinal 
      detachment, QT-prolongation and dysglycemia, the United States Food and Drug 
      Administration (FDA) issued a black box warning for FQ for systemic use in 2016 
      and updated warnings for FQ several times since then. Of note, in December 2018, 
      FDA issued several "black box warnings" against FQ with the latest safety 
      announcement warning about an increased risk of ruptures in the aorta blood 
      vessel in certain patients. Recently, many studies have indicated an association 
      between FQ and an increase risk of AA and AD. However, the exact mechanism of 
      FQ-induced AA/AD remains unclear. This review aims to highlight the latest 
      research progress of the alarming association between FQ and AA/AD. Moreover, 
      molecular mechanisms of FQ in increasing risk of AA and AD are explored. 
      Hopefully, this review can provide novel insights into FQ-increased the risk of 
      AA/AD and a starting place for stewardship interventions.
CI  - (c) 2021. The Author(s).
FAU - Jun, Cui
AU  - Jun C
AD  - Department of Cardiothoracic Surgery, Xiangyang Central Hospital, Affiliated 
      Hospital of Hubei University of Arts and Science, Xiangyang, 441000, Hubei, 
      China.
FAU - Fang, Bian
AU  - Fang B
AUID- ORCID: 0000-0002-8299-2263
AD  - Department of Pharmacy, Featured Preparations of Vitiligo Xiangyang Key 
      Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University 
      of Arts and Science, Xiangyang, 441000, Hubei, China. bianfang45@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210928
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fluoroquinolones)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aortic Dissection/*chemically induced/diagnostic imaging/epidemiology/prevention 
      & control
MH  - Animals
MH  - Anti-Bacterial Agents/*adverse effects
MH  - Antimicrobial Stewardship
MH  - Aortic Aneurysm/*chemically induced/diagnostic imaging/epidemiology/prevention & 
      control
MH  - Female
MH  - Fluoroquinolones/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC8477541
OTO - NOTNLM
OT  - Adverse event
OT  - Aortic aneurysm
OT  - Aortic dissection
OT  - Fluoroquinolones
COIS- The authors have no conflict of interest that are directly relevant to the 
      content of this article.
EDAT- 2021/09/30 06:00
MHDA- 2022/01/19 06:00
PMCR- 2021/09/28
CRDT- 2021/09/29 05:35
PHST- 2021/01/20 00:00 [received]
PHST- 2021/09/08 00:00 [accepted]
PHST- 2021/09/29 05:35 [entrez]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/09/28 00:00 [pmc-release]
AID - 10.1186/s12872-021-02258-1 [pii]
AID - 2258 [pii]
AID - 10.1186/s12872-021-02258-1 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2021 Sep 28;21(1):470. doi: 10.1186/s12872-021-02258-1.